Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

Inclusion Criteria: 1. Age: 30-50 Years; 2. Sex: All; 3. Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5; hematuria or microalbuminuria; eGFR\>90 mL/min/1.73m2; 4. Patients with microscopic hematuria only; 5. Patients with microscopic hematuria and microalbuminuria: 30-300mg/24h or urine albumin/creatinine: 30-300mg/g; 6. No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment. Exclusion Criteria: 1. With primary or secondary kidney disease, including IgA nephropathy, membranous nephropathy, lupus nephropathy, benign renal arterioles, etc.; 2. Patients with a history of angioedema; 3. Hypovolemia or hypotension (systolic blood pressure less than 90mmHg and/or diastolic blood pressure less than 60mmHg); 4. Pregnant and lactating women; 5. Patients with bilateral renal artery stenosis or unilateral renal artery stenosis with solitary kidney; 6. Hyperkalemia, blood potassium\>5.5mmol/L; 7. Severe aortic stenosis, severe mitral stenosis; 8. Treatment of drug allergy; 9. Hypertension or other diseases that may require treatment with angiotensin-converting enzyme inhibitors; 10. Disagree to participate in this research.